TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name Anti-TIGIT antibody
Drug Type Antibody
Toxicity Organism Test Type Route(Dose)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 938
Ref_1
Pair Name Cordycepin, Anti-TIGIT antibody
Partner Name Cordycepin
Disease Info [ICD-11: 2B90.Z] Colon cancer Investigative
Biological Phenomena Reshaped-->Tumor immune microenvironment
Gene Regulation Up-regulation Expression CD226 KEGG ID N.A.
In Vitro Model MC-38 Mouse colon adenocarcinoma Mus musculus (Mouse) CVCL_B288
CT26 Mouse colon adenocarcinoma Mus musculus (Mouse) CVCL_7254
In Vivo Model 1×10⁶ MC38 and CT26 cells were injected into the right abdomen of C57BL/6J and Balb/c mice.
Result The combination therapy group increased DCs in the tumor immune microenvironment and promoted cellular interaction with CD4 T cell and CD8 T cell populations while decreasing Treg cell interactions. In conclusion, cordycepin with anti-TIGIT therapy in colon cancer could reshape the tumor immune microenvironment and have notable anticancer effects.
03. Reference
No. Title Href
1 Single-cell RNA sequencing indicates cordycepin remodels the tumor immune microenvironment to enhance TIGIT blockade's anti-tumor effect in colon cancer. Int Immunopharmacol. 2024 Jan 5;126:111268. doi: 10.1016/j.intimp.2023.111268. Click
It has been None visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP